Wedbush lowers Perspective Therapeutics stock price target to $7
Wedbush reduced its price target for Perspective Therapeutics (NYSE:CATX) to $7 from $9, citing adjusted capital raise assumptions. The stock is down 69% YTD. Analysts have mixed views, with targets ranging from $4 to $14. The company's cash position and burn rate are noted.
How this was made
The 30-second read
Why it matters
The mixed analyst sentiment creates volatility; the lower target from Wedbush may dominate short‑term price action.
Market read
Analyst target revisions are a primary catalyst for price movement in micro‑cap biotech stocks.
What to watch
Potential upcoming trial data or partnership announcements could offset current cash‑burn concerns.
Background
Perspective Therapeutics is a radiopharmaceutical developer with multiple analyst coverage updates in the same period.
Ticker impact
Wedbush lowered its price target on Perspective Therapeutics (CATX) to $7 from $9, citing revised capital raise assumptions and cash burn concerns.
likely pressure as investors price in the lower valuation and cash‑burn risk
Analyst downgrade with a new lower price target typically leads to short‑term downside for a micro‑cap biotech.
Market effects
May weigh on other small‑cap biotech stocks as analysts scrutinize cash‑burn metrics.
Limited to US biotech sector.
Minimal beyond niche biotech investors.
Counterpoint
Some analysts (BMO, BTIG) maintain higher targets, suggesting upside if cash‑burn improves.
Key entities
- companyPerspective Therapeutics Inc
Biotech firm developing radioligand therapies (ticker CATX).
- analystWedbush Securities
Equity research firm that cut the price target.
